ADVM רווח נקי למניה (EPS TTM) Adverum Biotechnologies

Adverum Biotechnologies is implementing green chemistry principles and developing the innovative Ixo-vec system for retinal therapy. The TTM annual earnings per share reflect real efficiency dynamics, with the metric holding around -8.66. In the gene ophthalmology sector, business success is based on unique gene delivery methods that are securely protected by patent law against market dumping.
פילוחי מדדים פיננסיים ומדדי שוק עבור adverum.com (ADVM)

Net income per share (TTM) measures the portion of annual income attributable to a single security. The calculation is based on a 12-month rolling window, which neutralizes seasonality and reveals the actual profitability of the business. By analyzing the 12-month net income per share trend, an investor assesses the sensitivity of earnings to market changes. For Adverum Biotechnologies (ADVM), this metric reflects the efficiency of cost restructuring. The transparency of the gene therapy pipeline allows for the correlation of current financial results with the potential for future clinical success.